Who are EndoTAG-1 and Gemcitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zavzpret, TEBENTAFUSP, Qulipta, Vyepti, Nurtec Odt, Ubrelvy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/endotag-1-and-gemcitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

EndoTAG-1 and Gemcitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EndoTAG-1 and Gemcitabine (EndoTAG-1 and Gemcitabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Peptide. Area: Oncology.

phase 2 Peptide Tumor vasculature Oncology Small molecule Live · refreshed every 30 min

Target snapshot

EndoTAG-1 and Gemcitabine (EndoTAG-1 and Gemcitabine) — MediGene. EndoTAG-1 is a peptide that targets the tumor vasculature, while Gemcitabine is a nucleoside analog that interferes with DNA synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
EndoTAG-1 and Gemcitabine TARGET	EndoTAG-1 and Gemcitabine	MediGene	phase 2	Peptide	Tumor vasculature
Zavzpret	Zavegepant Hydrochloride	Pfizer	marketed	Calcitonin Gene-related Peptide Receptor Antagonist	Calcitonin gene-related peptide type 1 receptor	2023-01-01
TEBENTAFUSP	TEBENTAFUSP		marketed	Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC]		2022-01-01
Qulipta	ATOGEPANT	AbbVie	marketed	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	Calcitonin gene-related peptide type 1 receptor	2021-01-01
Vyepti	EPTINEZUMAB	Lundbeck Seattle BioPharmaceuticals, Inc.	marketed	Calcitonin Gene-related Peptide Antagonist [EPC]	Calcitonin gene-related peptide 1	2020-01-01
Nurtec Odt	rimegepant	Pfizer	marketed	Calcitonin Gene-related Peptide Receptor Antagonist	calcitonin gene-related peptide receptor	2020-01-01
Ubrelvy	UBROGEPANT	AbbVie	marketed	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	Calcitonin gene-related peptide type 1 receptor	2019-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Peptide class)

MediGene · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EndoTAG-1 and Gemcitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/endotag-1-and-gemcitabine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab